{"id":"https://genegraph.clinicalgenome.org/r/45cebd1c-39c1-4a7c-b405-451511136ad4v2.2","type":"EvidenceStrengthAssertion","dc:description":"*BVES* (Blood Vessel Epicardial Substance) a.k.a *POPDC1* (Popeye Domain-Containing 1) is one of the genes of the Popeye Domain in addition to *POPDC2* and *POPDC3*. It is an evolutionarily conserved membrane protein with a molecular function in the establishment and/or maintenance of cell integrity. It is expressed in the cardiac and the skeletal muscle and plays an important role in the development and the maintenance of these tissues. POPDC1*BVES* is associated with autosomal recessive limb-girdle muscular dystrophy (type 2X  included), where the main clinical features are slowly progressive proximal muscle weakness in lower limbs, usually associated with cardiac disturbances including arrhythmia. *BVES* was first reported in relation to autosomal recessive limb-girdle muscular dystrophy type 2X by Schindler et al. in 2016 (PMID: 26642364), who provided one of the most complete clinical and molecular descriptions with functional studies. More than 70 variants have been identified in *BVES* POPDC1 but only around 49 with clinical significance are assumed to cause LGMD2X. ClinVar reports at least 10 pathogenic/likely pathogenic variants in *BVES*. Summary of Case Level Data (12 points): Variants in this gene have been reported in at least 7 probands in 5 publications (PMID: 26642364, 31119192, 33310206, 35660068, 35718670). Variants in this gene segregated with disease in 3 additional family members. The mechanism for disease is biallelic loss of function. Functional studies showed that mutant variants lead to important reduction of POPDC1 protein in cAMP affinity in skeletal muscle from patients in addition to impaired membrane trafficking. A certain clinical variability was noted, within the same family and among unrelated individuals. This variability relates to the age of onset of the disease within the same family (PMID:26642364, PMID:31119192), the severity of the phenotype and the progression of the disease (PMID:33310206). Individuals with nonsense variants leading to premature truncation of the protein product appear to display a more severe phenotype (PMID: 33310206). Summary of experimental data (2 points): This gene-disease relationship is supported by limited experimental evidence. Expression studies showed that POPDC1 is prominently expressed in the sarcolemma in healthy muscle fibers, while in affected muscles, a significant reduction in membrane localization of both POPDC1 and POPDC2 was observed (PMID: 10882522, 27347491, 31119192). In summary, *BVES* is definitively associated with autosomal recessive limb-girdle muscular dystrophy type 2X. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time.\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/45cebd1c-39c1-4a7c-b405-451511136ad4","GCISnapshot":"https://genegraph.clinicalgenome.org/r/31a0db34-cad3-4746-a40f-2912318dfbd2","calculatedEvidenceStrength":"Definitive","changes":{"id":"cg:expertPanelChange"},"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/31a0db34-cad3-4746-a40f-2912318dfbd2_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10151","date":"2024-08-29T19:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/31a0db34-cad3-4746-a40f-2912318dfbd2_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10151","date":"2024-08-29T16:49:23.945Z","role":"Publisher"}],"curationReasons":["ErrorClarification"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/31a0db34-cad3-4746-a40f-2912318dfbd2_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/31a0db34-cad3-4746-a40f-2912318dfbd2_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bc0fbf52-e50e-4ff9-9176-dd001a082e2c_family_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31119192","rdfs:label":"Family 2","estimatedLodScore":0.25,"family":{"id":"https://genegraph.clinicalgenome.org/r/bc0fbf52-e50e-4ff9-9176-dd001a082e2c","type":"Family","rdfs:label":"Family 2","ethnicity":{"id":"cg:NotHispanicOrLatino"}},"meetsInclusionCriteria":false,"phenotype":{"id":"obo:HP_0006785"},"phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1},{"id":"https://genegraph.clinicalgenome.org/r/fc37f52d-3564-4691-89e7-e971411a15d1_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35660068","rdfs:label":"Pakistan","estimatedLodScore":1.7,"family":{"id":"https://genegraph.clinicalgenome.org/r/fc37f52d-3564-4691-89e7-e971411a15d1","type":"Family","rdfs:label":"Pakistan","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/0cbbaede-9dad-42b0-bee9-ea4c72299a4a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35660068","rdfs:label":"IV.1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":15,"allele":{"id":"https://genegraph.clinicalgenome.org/r/ce818ef8-9b3e-4c3d-bc2e-4eb5ada05206","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001199563.2(BVES):c.457C>T (p.Gln153Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/624258"}},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Elevated CK (16,000 UI/l), no muscle weakness, Sinus bradycardia (minimal heart rate 30/min), disturbance of repolarization; asymptomatic second degree AV-block during exercise test","phenotypes":["obo:HP_0001688","obo:HP_0030234"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/8618ebd2-419c-49ab-abca-b39c55ca659d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35660068","allele":{"id":"https://genegraph.clinicalgenome.org/r/ce818ef8-9b3e-4c3d-bc2e-4eb5ada05206"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}}},"phenotypeFreeText":"No muscle weakness, sinus bradycardia and an asymptomatic second degree AV-block during exercise. ","phenotypeNegativeAlleleNegative":4,"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0001688","obo:HP_0030234","obo:HP_0001678"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/0cbbaede-9dad-42b0-bee9-ea4c72299a4a"}},{"id":"https://genegraph.clinicalgenome.org/r/13affbd0-7d77-4bcd-82dd-5a01bc396e95_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31119192","rdfs:label":"North-Africa","estimatedLodScore":0.73,"family":{"id":"https://genegraph.clinicalgenome.org/r/13affbd0-7d77-4bcd-82dd-5a01bc396e95","type":"Family","rdfs:label":"North-Africa","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/8ea7bdc8-8e10-417d-a01b-0c4387cd137a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31119192","rdfs:label":"A I-1,","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":27,"allele":{"id":"https://genegraph.clinicalgenome.org/r/38558115-f65f-470e-af19-2e2a0b98876e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001199563.2(BVES):c.816+2T>C","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/626313"}},"detectionMethod":"WES was performed by the CNRGH on DNA samples from patients 1 and 2 and their mother. Variants were annotated and filtered using an in-house-developed software system (PolyWeb).","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/9a84228b-4251-4e2e-9cde-28c789776b52_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31119192","allele":{"id":"https://genegraph.clinicalgenome.org/r/38558115-f65f-470e-af19-2e2a0b98876e"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"Heart arrhythmia","phenotypeNegativeAlleleNegative":1,"phenotypePositiveAllelePositive":2,"proband":{"id":"https://genegraph.clinicalgenome.org/r/8ea7bdc8-8e10-417d-a01b-0c4387cd137a"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/c91f1cf6-0fbb-43b0-bb99-91c02fecfd4d_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26642364","rdfs:label":"Albania","estimatedLodScore":1.45,"family":{"id":"https://genegraph.clinicalgenome.org/r/c91f1cf6-0fbb-43b0-bb99-91c02fecfd4d","type":"Family","rdfs:label":"Albania","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/64c02ea2-49b5-4dcd-bc03-72ec4668e428","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26642364","rdfs:label":"III-2","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":12,"allele":{"id":"https://genegraph.clinicalgenome.org/r/1fca4561-69c7-4df6-9b08-809c38ef6dc9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001199563.2(BVES):c.602C>T (p.Ser201Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA351648"}},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Progressive muscle weakness affecting muscles of the shoulders and the hips, associated with cardiac abnormalities (Usually arrhythmia)","phenotypes":["obo:HP_0003325","obo:HP_0001279","obo:HP_0030234"],"previousTesting":true,"previousTestingDescription":"Medical Research Council Scale for Muscle Strength (MRC) was used for muscle testing. CK level, ECG, Holter monitoring, the head-up tilt test, the endocavitary electrophysiological study and echocardiography were also performed.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/15809452-4ba0-4681-9bbc-27141696c3ff_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26642364","allele":{"id":"https://genegraph.clinicalgenome.org/r/1fca4561-69c7-4df6-9b08-809c38ef6dc9"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"Limb-girdle Muscular Dystrophy","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0011706","obo:HP_0001279","obo:HP_0003236","obo:HP_0001688","obo:HP_0003325"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/64c02ea2-49b5-4dcd-bc03-72ec4668e428"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/64c02ea2-49b5-4dcd-bc03-72ec4668e428_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/64c02ea2-49b5-4dcd-bc03-72ec4668e428"},{"id":"https://genegraph.clinicalgenome.org/r/15809452-4ba0-4681-9bbc-27141696c3ff","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/15809452-4ba0-4681-9bbc-27141696c3ff_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/15809452-4ba0-4681-9bbc-27141696c3ff_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Patient skeletal muscle showed reduced membrane localization and increased abnormal perinuclear localization of both BVES (POPDC1) and POPDC2 (605823), suggesting that the mutation causes a defect in plasma membrane trafficking. In vitro functional assays showed that the S201F mutant protein had an approximately 50% reduction in affinity for cAMP compared to wildtype. The S201F mutation also impaired the ability of BVES to increase surface expression of the potassium channel TREK1 (KCNK2; 603219) in Xenopus oocytes. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/4f512cd7-3f55-444b-b156-0399cf0a2547_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4f512cd7-3f55-444b-b156-0399cf0a2547","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35718670","rdfs:label":"China P1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":34,"allele":{"id":"https://genegraph.clinicalgenome.org/r/c00b26f1-e732-48ba-b94d-8466cbcce9e4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001199563.2(BVES):c.262C>T (p.Arg88Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA145452482"}},"detectionMethod":"Targeted next-generation sequencing (NGS) covering 603 muscular disorder-related genes","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0003326","obo:HP_0001962","obo:HP_0025435","obo:HP_0030878","obo:HP_0030234","obo:HP_0006785","obo:HP_0002650","obo:HP_0011703"],"previousTesting":true,"previousTestingDescription":"Medical Research Council grade: hip flexors 4 + /4, hip extensors 4/3, and hip adductors/abductors 4 + /4","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/a7aa047e-54f3-4020-9572-e9a8aa566a95_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35718670","allele":{"id":"https://genegraph.clinicalgenome.org/r/c00b26f1-e732-48ba-b94d-8466cbcce9e4"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/a7aa047e-54f3-4020-9572-e9a8aa566a95","type":"EvidenceLine","dc:description":"1.5 is a conservative score until we find more evidence.","calculatedScore":5.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a7aa047e-54f3-4020-9572-e9a8aa566a95_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/a7aa047e-54f3-4020-9572-e9a8aa566a95_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In vitro functional studies provide some evidence that the p.Arg88Ter variant may slightly impact protein function.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/16583bfb-7359-4ea6-a23d-20097d028c3f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/16583bfb-7359-4ea6-a23d-20097d028c3f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31119192","rdfs:label":"Patient 4","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":39,"allele":{"id":"https://genegraph.clinicalgenome.org/r/ed27e39d-837b-478d-ae79-4ea1b5f4e6d6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001199563.2(BVES):c.1A>G (p.Met1Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/626315"}},"detectionMethod":"WES was performed using the SureSelect XT Human All Exon V6 enrichment kit (Agilent Technologies), followed by paired-end sequencing (2 Ã— 150 bp) on the HiSeq3000 sequencer (Illumina). Reads were mapped, and variants were called and annotated with the BCBio pipeline.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Myalgia in the calves at the age of 39, six months after starting fibrate therapy. Symptoms resolved after stopping the therapy. No muscle signs were found on further investigation.","phenotypes":"obo:HP_0006785","previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/5df11df1-2574-4014-95c0-4912ca8d7da5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31119192","allele":{"id":"https://genegraph.clinicalgenome.org/r/ed27e39d-837b-478d-ae79-4ea1b5f4e6d6"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/5df11df1-2574-4014-95c0-4912ca8d7da5","type":"EvidenceLine","dc:description":"This is a conservative scoring in absence of relevant supportive functional evidence","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5df11df1-2574-4014-95c0-4912ca8d7da5_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/5df11df1-2574-4014-95c0-4912ca8d7da5_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"To examine POPDC1 and POPDC2 at the plasma membrane,  IHC stainings was performed in patient and control muscle samples. Both POPDC1 and POPDC2 were abundantly present at the plasma membrane of control skeletal muscle. In all patient samples, however, both POPDC1 and POPDC2 were drastically diminished at the sarcolemma. Levels of SGCA, used as a control marker for sarcolemmal proteins, remained normal in the patient samples with similar staining patterns and intensities as for control samples.","functionalDataSupport":"No"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/81c4e1c6-7798-4893-af02-ca54f076cf0f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/81c4e1c6-7798-4893-af02-ca54f076cf0f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31119192","rdfs:label":"Patient 3","ageType":"AgeAtReport","ageUnit":"Years","ageValue":43,"allele":{"id":"https://genegraph.clinicalgenome.org/r/c00b26f1-e732-48ba-b94d-8466cbcce9e4"},"detectionMethod":"WES data of this patient were processed by the Genomics Platform at the Broad Institute MIT and Harvard (Boston, MA) and analyzed by the team at the John Walton Muscular Dystrophy Research Centre, Newcastle University.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Slowly progressive proximal muscle weakness in lower limbs, difficulties walking up hills and climbing stairs around the age of 35. A few years later, upper limbs were involved. Physical examination showed more proximal than distal muscle weakness, more marked in lower limbs and affecting the anterior tibial muscles. Scapular winging was also found. ","previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/3379acbd-f882-4a0d-adae-8151351d7633_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31119192","allele":{"id":"https://genegraph.clinicalgenome.org/r/c00b26f1-e732-48ba-b94d-8466cbcce9e4"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/3379acbd-f882-4a0d-adae-8151351d7633","type":"EvidenceLine","dc:description":"This is a premature Termination Codon.","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3379acbd-f882-4a0d-adae-8151351d7633_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/a1e05bb2-07de-420f-93cc-446f1f40671b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a1e05bb2-07de-420f-93cc-446f1f40671b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33310206","rdfs:label":"Patient 5","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":16,"allele":{"id":"https://genegraph.clinicalgenome.org/r/e211685a-a1e5-4612-8513-78844af6b5e2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001199563.2(BVES):c.427A>T (p.Arg143Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/1163853"}},"detectionMethod":"Next generation sequencing of 77 myopathy related genes ","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"Neurological examination showed bilateral scapular winging, pectoral atrophy with inverted axillary folds and atrophy of proximal limb muscles. Medical Research Council (MRC) grade 1 strength of bilateral biceps, triceps, quadriceps and right hamstrings. MRC grade 2 strength was observed in bilateral pectoralis major, brachioradialis, hip adductors, and left hamstrings. Left iliopsoas and right gluteus medius and maximus were MRC grade 4-, while bilateral deltoids, infraspinatus, right\niliopsoas and left gluteus medius and maximus were MRC grade 4. Distal upper and lower limb muscles were spared on isometric testing; however, he had mild difficulty walking on his heels and toes.","phenotypes":"obo:HP_0006785","previousTesting":true,"previousTestingDescription":"Medical Research Council (MRC) grade 1 strength of bilateral biceps, triceps, quadriceps and right hamstrings. MRC grade 2 strength was observed in bilateral pectoralis major, brachioradialis, hip adductors, and left hamstrings. Left iliopsoas and right gluteus medius and maximus were MRC grade 4-, while bilateral deltoids, infraspinatus, right iliopsoas and left gluteus medius and maximus were MRC grade 4. Distal upper and lower limb muscles were spared on isometric testing; however,\nhe had mild difficulty walking on his heels and toes. Blood chemistry showed a serum ck level of 4054 UI/l. Nerve conduction study was normal, but Needle EMG showed myopathic patterns in proximal upper and lower limbs muscles. Electrocardiogram and 24-h Holter monitoring demonstrated sinus\nbradycardia with 1st degree AV block. Echocardiogram was normal. Genetic evaluation for facioscapulohumeral muscular dystrophy (FSHD) types 1 and 2 was normal","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/a8485a3d-aa60-4e38-922a-ecc6f20d51c4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33310206","allele":{"id":"https://genegraph.clinicalgenome.org/r/e211685a-a1e5-4612-8513-78844af6b5e2"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/a8485a3d-aa60-4e38-922a-ecc6f20d51c4","type":"EvidenceLine","dc:description":"This mutation is predicted to result in truncated protein. ","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a8485a3d-aa60-4e38-922a-ecc6f20d51c4_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/0cbbaede-9dad-42b0-bee9-ea4c72299a4a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0cbbaede-9dad-42b0-bee9-ea4c72299a4a"},{"id":"https://genegraph.clinicalgenome.org/r/8618ebd2-419c-49ab-abca-b39c55ca659d","type":"EvidenceLine","dc:description":"This is a conservative scoring in absence of functional evidence","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8618ebd2-419c-49ab-abca-b39c55ca659d_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/8ea7bdc8-8e10-417d-a01b-0c4387cd137a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8ea7bdc8-8e10-417d-a01b-0c4387cd137a"},{"id":"https://genegraph.clinicalgenome.org/r/9a84228b-4251-4e2e-9cde-28c789776b52","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9a84228b-4251-4e2e-9cde-28c789776b52_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/31a0db34-cad3-4746-a40f-2912318dfbd2_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/31a0db34-cad3-4746-a40f-2912318dfbd2_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/803187f5-023e-42cf-9a0b-2d205444e0f9","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5bc73a15-3702-4235-ac72-b430c28f716f","type":"Finding","dc:description":"Frozen sections of mouse myocardial tissue were immunohistochemically stained with antibodies directed against POPDC1 and, as a marker of ventricular conduction tissue. POPDC1 is expressed at higher levels in the atria, His bundle and Purkinje fibres in comparison to the ventricular working myocardium.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27347491","rdfs:label":"Expression of POPDC1 in the murine heart","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6cb5ffe2-772b-4f1d-972a-4733a793561c","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e0f6cd3a-4073-4b97-a70a-db00515d28ae","type":"Finding","dc:description":"In healthy skeletal muscle fibers, POPDC1 andPOPDC2 are prominently expressed in the sarcolemma. in skeletal muscle biopsies of the 2 affected siblings, a significant reduction in membrane\nlocalization of both POPDC1 and POPDC2 is observed.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26642364","rdfs:label":"Membrane trafficking of POPDC1 is affected in muscle biopsy","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/0e37822c-38b5-4548-ad93-1db9910a5cc0","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/962795c3-d3bb-4a4c-8450-c50c92ba16b1","type":"Finding","dc:description":"Northern blot analysis of murine Pop genes revealed the expression of all three Pop genes in adult skeletal muscle. A 4.2-kb species was present in heart and muscle, while a 2-kb\nPop1 mRNA species was detected in all muscle tissues.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10882522","rdfs:label":"Tissue Distribution of POPDC transcripts in the adult","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/17d74921-8c3d-4f0d-a322-85d9031f66f6","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2da3bce0-9f73-45f7-bc03-79da1a67a27d","type":"Finding","dc:description":"IHC  staining in patient and control muscle samples was performed to examine POPDC1 and POPDC2 at the plasma membrane. Both POPDC1 and POPDC2 were abundantly present at the plasma membrane of control skeletal muscle. In all patient samples, however, both POPDC1 and\nPOPDC2 were drastically diminished at the sarcolemma. Levels of SGCA, used as a control marker for sarcolemmal proteins, remained normal in the patient samples with similar staining patterns and intensities as for control samples.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31119192","rdfs:label":"POPDC1 and PODPC2 at the sarcolemma in muscle of patients","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":2}],"evidenceStrength":"Definitive","sequence":8893,"specifiedBy":"GeneValidityCriteria9","strengthScore":14,"subject":{"id":"https://genegraph.clinicalgenome.org/r/f_Rw9TxRgzs","type":"GeneValidityProposition","disease":"obo:MONDO_0015152","gene":"hgnc:1152","modeOfInheritance":"obo:HP_0000007"},"version":"2.2","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_31a0db34-cad3-4746-a40f-2912318dfbd2-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}